Cargando…

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

OBJECTIVE: To describe clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). DESIGN: Electronic survey August 2020–May 2021. RESULTS: 96% of 171 (121 APT, 50 PC), initially presented as macro/giant tumours,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burman, Pia, Trouillas, Jacqueline, Losa, Marco, McCormack, Ann, Petersenn, Stephan, Popovic, Vera, Theodoropoulou, Marily, Raverot, Gerald, Dekkers, Olaf M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513638/ https://www.ncbi.nlm.nih.gov/pubmed/36018781 http://dx.doi.org/10.1530/EJE-22-0440

Ejemplares similares

Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment
por: Burman, Pia, et al.
Publicado: (2023)

Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors
por: Roche, Magali, et al.
Publicado: (2015)

How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020
por: Trouillas, Jacqueline, et al.
Publicado: (2020)

The epidemiology of aggressive pituitary tumors (and its challenges)
por: Dekkers, Olaf M., et al.
Publicado: (2020)

Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability
por: Wierinckx, Anne, et al.
Publicado: (2018)

Endocrinology in the time of COVID-19: Management of pituitary tumours
por: Fleseriu, Maria, et al.
Publicado: (2020)

Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ
por: Xekouki, Paraskevi, et al.
Publicado: (2018)

The evolution in pituitary tumour classification: a clinical perspective
por: Lenders, Nele F, et al.
Publicado: (2023)

Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
por: Lamb, Lydia S., et al.
Publicado: (2020)

Glucocorticoid Receptors Are Making a Comeback in Corticotroph Tumorigenesis
por: Theodoropoulou, Marily
Publicado: (2021)

Silent gonadotroph pituitary neuroendocrine tumor in a patient with tuberous sclerosis complex: evaluation of a possible molecular link
por: Regazzo, Daniela, et al.
Publicado: (2018)

Emerging and Novel Treatments for Pituitary Tumors
por: Ilie, Mirela Diana, et al.
Publicado: (2019)

Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas
por: Lee, Misu, et al.
Publicado: (2013)

Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations
por: Casar-Borota, Olivera, et al.
Publicado: (2020)

Genomics in Cushing’s Disease: The Dawn of a New Era
por: Reincke, Martin, et al.
Publicado: (2021)

Genetics of Cushing’s disease: from the lab to clinical practice
por: Theodoropoulou, Marily, et al.
Publicado: (2022)

The Microenvironment of Pituitary Tumors—Biological and Therapeutic Implications
por: Ilie, Mirela Diana, et al.
Publicado: (2019)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

Aggressive corticotroph tumors and carcinomas
por: Lasolle, Hélène, et al.
Publicado: (2022)

Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition?
por: Culpin, Elizabeth, et al.
Publicado: (2018)

Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours
por: Lenders, N. F., et al.
Publicado: (2022)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
por: Castellnou, Solène, et al.
Publicado: (2020)

At PS171 (ASTERIX)
Publicado: (1983)

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells
por: Cuny, Thomas, et al.
Publicado: (2016)

OR23-04 SST5 Expression and USP8 Mutation in Functioning and Silent Corticotroph Pituitary Tumors
por: castellnou, Solene, et al.
Publicado: (2020)

Costs and Its Determinants in Pituitary Tumour Surgery
por: Dekkers, Alies J., et al.
Publicado: (2022)

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas
por: Buchfelder, Michael, et al.
Publicado: (2020)

171th RB Meeting
Publicado: (2005)

Memorandum: PS171 experiment
por: Klempt, E
Publicado: (1982)

Primary glomus tumour of the pituitary gland: diagnostic challenges of a rare and potentially aggressive neoplasm
por: Quah, Boon Leong, et al.
Publicado: (2020)

Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?
por: Petersenn, Stephan, et al.
Publicado: (2019)

Temozolomide in aggressive pituitary adenomas and carcinomas
por: Ortiz, Leon D., et al.
Publicado: (2012)

Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications
por: Miermeister, Christian P., et al.
Publicado: (2015)

Correction to “Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment”
Publicado: (2023)

Pituitary Crooke Cell Adenoma: Two Cases of an Aggressive Pituitary Adenoma
por: Taiwo, Adeyinka, et al.
Publicado: (2023)

Health Tract, No. 171: Great Eaters
Publicado: (1863)

Health Tract, No. 171: Great Eaters
Publicado: (1865)

Erratum: Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications
por: Miermeister, Christian P., et al.
Publicado: (2016)

Editorial: Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments
por: Wang, Renzhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qfrrqok4e85p88moevuv1f63cl